BiotechTube

Phytocannabinoid cannabidiol (CBD)

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alcohol Use Disorder

Conditions

Alcohol Use Disorder

Trial Timeline

Sep 1, 2019 → Mar 16, 2022

NCT ID
NCT03252756

About Phytocannabinoid cannabidiol (CBD)

Phytocannabinoid cannabidiol (CBD) is a phase 1/2 stage product being developed by Tilray for Alcohol Use Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03252756. Target conditions include Alcohol Use Disorder.

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT03252756Phase 1/2Completed

Competing Products

20 competing products in Alcohol Use Disorder

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
LanifibranorInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
LY686017 + PlaceboEli LillyPhase 2
52
LY3537031 + PlaceboEli LillyPhase 3
77
AD04 (ondansetron) + Matching placeboAdial PharmaceuticalsPhase 3
69
GODEX + PlaceboCelltrionPhase 3
77
Colesevelam HclDaiichi SankyoPhase 2
52
ASP9831 + PlaceboAstellas PharmaPhase 2
52
ASP8062 + PlaceboAstellas PharmaPhase 2
52
LY686017 + PlaceboEli LillyPhase 2
52
Mazdutide + PlaceboEli LillyPhase 2
52
opioid receptor kappa antagonistEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 2
52
LY2196044 + placeboEli LillyPhase 2
52

Other Products from Tilray

Cannabidiol (CBD) Oil Capsules + Sunflower Lecithin Oil in CapsulePhase 3
72
TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg) + TN-C200M2 oral capsules (CBD 200 mg)Phase 2
47
High THC/Low CBD Cannabis + High THC/High CBD Cannabis + Low THC/Low CBD CannabisPhase 2
47
TN-TC11G + Temozolomide Oral ProductPhase 1/2
36
Cannabidiol + PlacebosPhase 1/2
36